Advisors Asset Management Inc. boosted its holdings in Clovis Oncology (NASDAQ:CLVS) by 1,017.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 56,668 shares of the biopharmaceutical company’s stock after purchasing an additional 51,597 shares during the quarter. Advisors Asset Management Inc.’s holdings in Clovis Oncology were worth $218,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Amalgamated Bank lifted its stake in Clovis Oncology by 23.9% during the 2nd quarter. Amalgamated Bank now owns 7,283 shares of the biopharmaceutical company’s stock valued at $331,000 after acquiring an additional 1,406 shares in the last quarter. Greenwood Capital Associates LLC lifted its stake in Clovis Oncology by 25.3% during the 2nd quarter. Greenwood Capital Associates LLC now owns 6,981 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 1,408 shares in the last quarter. MetLife Investment Advisors LLC raised its stake in shares of Clovis Oncology by 8.7% during the 2nd quarter. MetLife Investment Advisors LLC now owns 21,967 shares of the biopharmaceutical company’s stock worth $999,000 after purchasing an additional 1,764 shares during the period. NJ State Employees Deferred Compensation Plan raised its stake in shares of Clovis Oncology by 18.2% during the 2nd quarter. NJ State Employees Deferred Compensation Plan now owns 13,000 shares of the biopharmaceutical company’s stock worth $591,000 after purchasing an additional 2,000 shares during the period. Finally, PNC Financial Services Group Inc. raised its stake in shares of Clovis Oncology by 37.9% during the 2nd quarter. PNC Financial Services Group Inc. now owns 7,483 shares of the biopharmaceutical company’s stock worth $339,000 after purchasing an additional 2,056 shares during the period.

A number of research firms have recently commented on CLVS. Gabelli reiterated a “buy” rating on shares of Clovis Oncology in a research note on Monday, July 16th. JPMorgan Chase & Co. reiterated a “buy” rating and set a $71.00 target price on shares of Clovis Oncology in a research note on Friday, September 21st. Cann began coverage on Clovis Oncology in a research note on Wednesday, August 8th. They set a “hold” rating on the stock. ValuEngine upgraded Clovis Oncology from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 2nd. Finally, Zacks Investment Research cut Clovis Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, July 10th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $73.41.

Shares of Clovis Oncology stock opened at $26.73 on Friday. Clovis Oncology has a 52-week low of $26.39 and a 52-week high of $86.26. The stock has a market capitalization of $1.55 billion, a P/E ratio of -5.22 and a beta of 1.08. The company has a current ratio of 10.03, a quick ratio of 9.21 and a debt-to-equity ratio of 1.84.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.38) by ($0.56). Clovis Oncology had a negative net margin of 382.83% and a negative return on equity of 94.28%. The firm had revenue of $23.76 million during the quarter, compared to the consensus estimate of $22.44 million. During the same quarter in the prior year, the firm posted ($1.29) earnings per share. The company’s revenue was up 62.5% on a year-over-year basis. As a group, sell-side analysts forecast that Clovis Oncology will post -6.74 EPS for the current year.

Clovis Oncology Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Read More: What is the yield curve?

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.